RA Capital funds add 32,876 Artiva Biotherapeutics (ARTV) shares in buys

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. disclosed that investment vehicles managed by RA Capital Management, L.P. made net open-market purchases of 32,876 shares of its common stock. On June 25, 2026, a fund associated with RA Capital bought 31,000 shares at a weighted average price of $8.88 per share, and on June 26, 2026, a related account bought 1,876 shares at a weighted average price of $8.98 per share. Footnotes state these trades occurred in multiple transactions within price ranges of $8.62–$8.98 and $8.97–$9.00. After these transactions, RA Capital–managed entities collectively report indirect holdings in several blocks, including 16,795,919 shares in one fund, reflecting a large existing position with a relatively small incremental purchase.

Insider Trade Summary

Net Buyer: 32,876 shares

Net Buy 5 txns

Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M.

Role Director, 10% Owner | Director, 10% Owner | Director | Director | Director, 10% Owner | Director, 10% Owner

Bought 32,876 shs ($292K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,876	$8.98	$17K
Purchase	Common Stock	31,000	$8.88	$275K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 17,955,642 shares (Indirect, See footnotes)

Footnotes (7)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.62 to $8.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
3. F3. Held directly by the Fund.
4. F4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
5. F5. Held directly by the Nexus Fund.
6. F6. Held directly by Nexus Fund III.
7. F7. Held directly by the Account.

Key Figures

Net shares purchased: 32,876 shares June 25 weighted average price: $8.88/share June 26 weighted average price: $8.98/share +4 more

7 metrics

Net shares purchased 32,876 shares Total open-market common stock buys reported in this Form 4

June 25 weighted average price $8.88/share 31,000-share open-market purchase on June 25, 2026

June 26 weighted average price $8.98/share 1,876-share open-market purchase on June 26, 2026

Price range June 25 trades $8.62–$8.98 Multiple transactions aggregated into June 25 weighted average

Price range June 26 trades $8.97–$9.00 Multiple transactions aggregated into June 26 weighted average

Largest fund holding 16,795,919 shares Common stock indirectly held by one RA Capital fund after transactions

Other indirect holdings 68,320; 826,832; 264,571 shares Additional ARTV common stock blocks in related RA Capital vehicles

Key Terms

weighted average price, pecuniary interest, separately managed account, indirect ownership, +1 more

5 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

pecuniary interest financial

"disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."

separately managed account financial

"and a separately managed account (the "Account")."

A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.

indirect ownership financial

"total_shares_following_transaction ... ownership_type": "indirect""

investment manager financial

"RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:21 PM Accepted by SEC EDGAR 06/29/2026 - 04:20 PM Learn about SEC filing dates

FAQ

What insider activity did RA Capital report in Artiva Biotherapeutics (ARTV)?

RA Capital–managed entities reported net open-market purchases of 32,876 Artiva Biotherapeutics shares. These trades were executed across two days at weighted average prices below $9 per share, modestly increasing already large indirect holdings in the company.

At what prices did RA Capital buy ARTV shares in this Form 4?

RA Capital–managed entities bought ARTV common stock at weighted average prices of $8.88 and $8.98 per share. Footnotes explain that underlying trades occurred in ranges of $8.62–$8.98 and $8.97–$9.00 across multiple individual transactions.

How many Artiva Biotherapeutics shares do RA Capital entities hold after these trades?

Following these transactions, one RA Capital fund reports 16,795,919 shares of ARTV common stock, with additional indirect positions of 68,320, 826,832, and 264,571 shares in other vehicles. These figures show substantial pre-existing exposure with a relatively small incremental purchase.

Who actually holds the ARTV shares reported in the RA Capital Form 4?

The ARTV shares are held by investment vehicles including RA Capital Healthcare Fund, RA Capital Nexus Fund, RA Capital Nexus Fund III, and a separately managed account. Footnotes state RA Capital Management and its principals disclaim beneficial ownership beyond their pecuniary interests in these entities.

Does the RA Capital Form 4 for ARTV involve derivative securities or options?

No derivative positions are shown in this Form 4; the derivativeSummary is empty. The reported activity relates only to ARTV common stock, reflecting straightforward open-market purchases and updated indirect share balances across RA Capital–managed investment vehicles.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/25/2026		P		31,000	A	$8.88(1)	16,794,043	I	See footnotes(2)(3)
Common Stock	06/26/2026		P		1,876	A	$8.98(4)	16,795,919	I	See footnotes(2)(3)
Common Stock								264,571	I	See footnotes(2)(5)
Common Stock								826,832	I	See footnotes(2)(6)
Common Stock								68,320	I	See footnotes(2)(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Nexus Fund, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Nexus Fund III, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.62 to $8.98 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

3. Held directly by the Fund.

4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.97 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

5. Held directly by the Nexus Fund.

6. Held directly by Nexus Fund III.

7. Held directly by the Account.

Remarks:

Laura Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	06/29/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	06/29/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund GP, LLC, the General Partner of RA Capital Nexus Fund, L.P.	06/29/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund III GP, LLC, the General Partner of RA Capital Nexus Fund III, L.P.	06/29/2026
	/s/ Peter Kolchinsky, individually	06/29/2026
	/s/ Rajeev Shah, individually	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)